Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perospirone augmentation of SSRIs or SNRIs for major depressive disorder
ChiCTR2200063354Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of perospirone in major depressive disorder (MDD) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Response rate at week 4 and week 8 and Remission rate at week 4 and week 8. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
perospirone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2200063354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063354.